Non-small cell lung carcinoma (NSCLC) comprises 80%–85% of lung cancer cases. EGFR
is involved in several cancer developments, including NSCLC. The EGFR pathway …

Approximately one third of all lung cancer patients in East Asia are never-smokers.
Furthermore, the proportion of lung cancer in never smokers (LCINS) has been increasing …

Non-small cell lung carcinoma (NSCLC) is the most common malignancy worldwide. The
signaling cascades are stimulated via genetic modifications in upstream signaling …

Introduction Air pollution may play an important role in the development of lung cancer in
people who have never smoked, especially among East Asian women. The aim of this study …

Introduction Most published guidelines for genomic biomarker testing in NSCLC reflect the
disease epidemiology and treatments readily available in Europe and North America …

Objectives Ramucirumab plus docetaxel prolongs survival in patients with non-small cell
lung cancer (NSCLC) with disease progression after platinum-based therapy. This phase II …

Purpose The new 8 th American Joint Committee on Cancer (AJCC)/International Union for
Cancer Control (UICC) lung cancer staging system was developed and internally validated …

Highlights•The present review highlights the emerging clinical relevance of MEK5/ERK5
signalling as a therapeutic target and prognostic factor in several top-leading diagnosed …

Lung cancer is the common fatal illness with the highest incidence and mortality globally.
Epidermal growth factor receptor overexpression by tumor cells is associated with …

Abstract Background Delta-like ligand 4-Notch (DLL4-Notch) signaling contributes to the
maintenance of chemotherapy-resistant cancer stem cells and tumor vasculature. Objective …